Vaccine Research Center

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Retrieved on: 
Tuesday, March 5, 2024
Infection, Fungal infection, CROI, NIH, AIDS, Vaccine Research Center, ACTG, Conference, Antibody, Safety, OPKO Health, Therapy, Pharmacokinetics, AIDS Clinical Trials Group, Modex, Trial of the century, HIV, HIV/AIDS, Immune system, Vaccine

WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus (HIV), at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.

Key Points: 
  • These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.
  • The study enrolled 52 participants and was conducted by the AIDS Clinical Trials Group (ACTG), a clinical trials network funded by the National Institute of Allergy and Infectious Diseases, NIH.
  • The antibody was safe and well-tolerated at all dose levels and via both intravenous and subcutaneous administration.
  • These clinical data on an HIV multispecific antibody inform the future advancement of such antibodies for the prevention and treatment of HIV and provide strong rationale for the development of current and future antibody products.

ATCC Announces Comprehensive and Rapid Response to NIAID Research Programs (CARRRP) Award from NIAID

Retrieved on: 
Tuesday, November 28, 2023
Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, NIAID, Disease, Acquisition, Vaccine Research Center, VRC, NIH Intramural Research Program, Air tasking order, Bioterrorism, Vaccine, Laboratory, DVM, IDIQ, API, Infection, COVID-19, Biomedical Research, NIH, MBA, Indefinite, Comprehensive, CGMP, Doctor of Philosophy, Active ingredient, Bangladesh Technical Education Board, Public, IRP, Pharmaceutical industry, ATCC

The Task Order is part of the Storage Facility Task Area under the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP).

Key Points: 
  • The Task Order is part of the Storage Facility Task Area under the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP).
  • NIAID’s CARRRP provides the capacity and capability for a broad range of services necessary to support and conduct comprehensive and rapid biomedical research.
  • Under the CARRRP Task Order, ATCC will manage critical biomaterials for the Vaccine Research Center (VRC), one of the three intramural divisions of NIAID’s Intramural Research Program (IRP).
  • “We look forward to working with NIAID and its Intramural Research Program as part of the CARRRP.”

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Retrieved on: 
Thursday, September 28, 2023
United States Department of Health and Human Services, DNA, Biomedical Advanced Research and Development Authority, Epstein–Barr virus, Therapy, Office of Inspector General, U.S. Department of Health and Human Services, HHS, SARS-CoV-2, Human services, Public, Infection, COVID-19, MSTAR, Administration for Strategic Preparedness and Response, DRS, Research, Antibody, Bangladesh Technical Education Board, Modex, Messenger, Vaccine Research Center, Administration, Development, OPKO Health, Merck, BARDA, Virus, NIH, Vaccine

The awarded funding will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology.

Key Points: 
  • The awarded funding will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology.
  • Additional funding of up to $109 million may be available from BARDA upon achieving particular milestones to develop multispecific antibodies targeting other viral pathogens such as influenza.
  • “We are excited to partner with BARDA to advance the potential of our MSTAR multispecific antibody platform as a versatile solution to major viral threats,” said Drs.
  • Gary Nabel and Elias Zerhouni, Co-Founders of ModeX and, respectively, President, Chief Executive Officer of ModeX and President of OPKO.

Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role

Retrieved on: 
Monday, June 5, 2023
MESO, US Foods, Center for Biologics Evaluation and Research, Mesoblast, Inflammatory bowel disease, Vaccine Research Center, MSB, FDA, Vaccine, BLA, Food, Inflammation, Pharmaceutical industry, Research

NEW YORK, June 04, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce that it has appointed Dr. Philip R. Krause, a member of the Board of Directors, to a formal strategic advisory role.

Key Points: 
  • NEW YORK, June 04, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce that it has appointed Dr. Philip R. Krause, a member of the Board of Directors, to a formal strategic advisory role.
  • The consulting agreement is in addition to Dr. Krause’s existing role as a non-executive director, the terms of which remain unchanged.
  • Dr. Krause will provide specialist regulatory advisory services and will be remunerated at an hourly rate.
  • The agreement is ongoing with either party able to terminate on 15 days written notice.

LinKinVax Just Completed a New Round of Financing, Initiated in 2022, for a Total of €7,3 M 

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Ooredoo, PIA, HPV, B cell, University, Coronaviridae, Biomedical Research, Chlamydia, HIV, Public health, Vaccine Research Center, Government, Vaccine, VRI, Infection, Immune system, UPEC, IQT, Cancer, IMRB, University of Paris-Est Marne-la-Vallée

LinKinVax’s innovative technology directly targets dendritic cells (“DC”), which play a crucial role in the immune system, stimulating and regulating immune responses.

Key Points: 
  • LinKinVax’s innovative technology directly targets dendritic cells (“DC”), which play a crucial role in the immune system, stimulating and regulating immune responses.
  • It is predicated on work by the Vaccine Research Institute/Inserm (VRI) in which Inserm, University of Paris Est Créteil (UPEC), and the Mondor Institute of Biomedical Research (IMRB) participate.
  • Englehart, Director, IQT International Ltd UK: “We are impressed by LinKinVax’s team and its vision for developing world-class vaccine technology.
  • This new financing, completed in December 2022, includes a seed funding from private shareholders, beginning of 2022.

TOMI Environmental Receives Order From National Institutes of Health (NIH); TOMI Products Now Deployed in Over 20 NIH Facilities Across 11 Divisions

Retrieved on: 
Thursday, October 20, 2022
Hydrogen, National Institute, U.S. Department of Defense Strategy for Operating in Cyberspace, NIEHS, Hydrogen peroxide, SEC, Government, Corrosion, Infection, VRC, IHP, National Institute of Dental and Craniofacial Research, Biosafety, NASDAQ, Annual report, COO, Restaurant, Decontamination, Hospital, Vaccine Research Center, HHS, Research, NIH, NIAID, DARPA, Police, National Institute of Environmental Health Sciences, Technology, Allergy, National Cancer Institute, RML, Rocky Mountain Laboratories, Disinfectant, Association, GLOBE, Office of Inspector General, U.S. Department of Health and Human Services, EPA, Forward-looking statement, COVID-19, NIDCR, Meat, School, NCI, Pharmaceutical industry

This purchase order reflects their continued implementation of SteraMist iHP technology within decontamination protocols to improve sterility and facility productivity.

Key Points: 
  • This purchase order reflects their continued implementation of SteraMist iHP technology within decontamination protocols to improve sterility and facility productivity.
  • In total, NIH has deployed approximately thirty (30) SteraMist machines across eleven (11) divisions, including National Institute of Allergy & Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS), National Institute of Dental and Craniofacial Research (NIDCR), National Cancer Institute (NCI), Vaccine Research Center (VRC), and Rocky Mountain Laboratories (RML).
  • Shane, COO of TOMI, states, SteraMist is used throughout many government agencies, and we take pride in supporting customers like NIH.
  • These forward-looking statements include, without limitation, statements relating to TOMIs ability to develop products for NIH and government use.

GreenLight Biosciences announces realignment to focus on near-term value drivers

Retrieved on: 
Wednesday, October 12, 2022
LinkedIn, U.S. Securities and Exchange Commission, Time, Securities Act of 1933, Therapy, Sickle cell disease, SEC, RNA transfection, Efficiency, Agriculture, Serum Institute of India, Vaccine, Annual report, Shingles, RNA, Twitter, Research, Program, Insecticide, Nasdaq, Solution, Goal, MITES, COVID-19, Health, Vaccine Research Center, Samsung Biologics, National, CEO, Social media, File, GLOBE, Forward-looking statement, Crop protection, GRNA, Pharmaceutical industry, Risk management, Management, Green-light

Our goals, ambition and mission remain unchanged as we hone the focus of our work to current market conditions, said Andrey Zarur, CEO of GreenLight.

Key Points: 
  • Our goals, ambition and mission remain unchanged as we hone the focus of our work to current market conditions, said Andrey Zarur, CEO of GreenLight.
  • The integration and streamlining of teams will help extend our runway and allow us to better focus on our near-term value drivers for human health and plant health.
  • This realignment comes following a range of cost cutting measures instituted earlier this year and will help us better position GreenLight for longer-term growth, said Andrey Zarur, CEO of GreenLight.
  • For additional information on GreenLight and potential risks associated with investing, please see our public filings at https://investors.greenlightbio.com/financial-information/sec-filings

Grid Biosciences Announces License Agreement with NIH for Epstein-Barr Virus Vaccine

Retrieved on: 
Monday, August 29, 2022
National, Human, CEO, National Institute, National Institute of Allergy and Infectious Diseases, Degenerative disease, Stomach, Hodgkin lymphoma, Laboratory, Infection, Vaccine, EBV, Burkitt lymphoma, Multiple sclerosis, Mouse, Nasopharyngeal carcinoma, NIH, Vaccine Research Center, Patent, NEW, Epstein–Barr virus, Infectious mononucleosis, NIAID, Lymphoma, List of life sciences, Cancer, Grid

NEW YORK, Aug. 29, 2022 /PRNewswire-PRWeb/ -- Grid Biosciences ("Grid"), a biotechnology company, today announced the signing of a license agreement for the development of a vaccine against Epstein-Barr virus ("EBV") with the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the National Institutes of Health ("NIH"). The agreement includes access to NIH's patent rights in EBV envelope proteins that the virus uses to gain entry into human cells.

Key Points: 
  • Grid Biosciences signs license agreement for the development of a vaccine against Epstein-Barr virus with the National Institute of Allergy and Infectious Diseases.
  • NEW YORK, Aug. 29, 2022 /PRNewswire-PRWeb/ -- Grid Biosciences ("Grid"), a biotechnology company, today announced the signing of a license agreement for the development of a vaccine against Epstein-Barr virus ("EBV") with the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the National Institutes of Health ("NIH").
  • The agreement includes access to NIH's patent rights in EBV envelope proteins that the virus uses to gain entry into human cells.
  • The forward-looking statements in this press release are based on information available to Grid as of the date hereof.

GreenLight Biosciences announces $109 million financing

Retrieved on: 
Friday, August 12, 2022
Securities Act of 1933, Serum Institute of India, RNA transfection, MITES, CEO, GLOBE, Failure, Private Securities Litigation Reform Act, SEC, COVID, Vaccine Research Center, Samsung, Shingles, Agriculture, National, Research, EPA, Annual report, Form 8-K, Crop protection, Company, Baird, Samsung Biologics, Goodwin Procter, Program, Therapy, Vaccine, ContiGroup Companies, RNA, Nathan Cummings Foundation, Intention, Â, GRNA, Symbiosis, COVID-19, Nasdaq, Solution, Credit Suisse, Health, Security (finance), Green-light

We are also delighted to welcome new investors who have decided to join GreenLight in our mission to feed the world and keep it healthy.

Key Points: 
  • We are also delighted to welcome new investors who have decided to join GreenLight in our mission to feed the world and keep it healthy.
  • GreenLight intends to use the net proceeds from the financing to advance its development of research and commercial programs and for working capital and general corporate purposes.
  • GreenLight Biosciences (Nasdaq: GRNA) aims to address some of the worlds biggest problems by delivering on the full potential of RNA for human health and agriculture.
  • For additional information on GreenLight and potential risks associated with investing, please see our public filings at https://www.sec.gov/edgar/browse/?CIK=1822691&owner=exclude.

Eleven Therapeutics Announces $22 Million in Seed Funding

Retrieved on: 
Tuesday, August 2, 2022
Vaccine Research Center, Infection, University, Bill, Bill & Melinda Gates Foundation, SAR, National Institutes of Health, Innovation, NIAID, CRADA, Innovate UK, RNA, CEO, National, Development, National Institute, Sirna Therapeutics, Cooperative research and development agreement, Cancer Research UK, Artificial intelligence, Sand, National Institute of Allergy and Infectious Diseases, Deep learning, Therapy, Degenerative disease, Cancer research, TEL, Cambridge Institute for Sustainability Leadership, Biotechnology, Disease, Patient, Sirna, Lists of countries and territories, Human Immunology, Structure–activity relationship, AI, Melinda Gates, Pharmaceutical industry, Medical device, RNA interference, 11

TEL AVIV, Israel and CAMBRIDGE, England, Aug 02, 2022 /PRNewswire/ -- Eleven Therapeutics, a biotechnology company leading the AI revolution in nucleic acid therapeutics, announced today that it has raised a total of $22 million in seed funding.

Key Points: 
  • Round includes $9 Million from the Bill & Melinda Gates Foundation, aimed at ushering in the next generation of RNAi therapeutics
    TEL AVIV, Israel and CAMBRIDGE, England, Aug 02, 2022 /PRNewswire/ -- Eleven Therapeutics , a biotechnology company leading the AI revolution in nucleic acid therapeutics, announced today that it has raised a total of $22 million in seed funding.
  • Importantly, the Gates Foundation's funding will promote wide accessibility of Eleven's ultimate treatments to people in need in developing countries.
  • "The future equity investment and grant funding from the Gates Foundation propels our revolutionary efforts of mapping the chemical space of oligonucleotide therapeutics.
  • Eleven Therapeutics ushers in the next generation of RNAi therapeutics by combining artificial intelligence (AI), massively parallel functional assays, and combinatorial chemistry.